01
IGF-1R
Activates the IGF-1 receptor; LR3 binds less strongly to IGF-binding proteins.
Long-acting IGF-1 analogue
IGF-1 LR3
IGF-1R
IGF-1 LR3 is an extended IGF-1 analogue with arginine at position 3 and reduced affinity for IGF-binding proteins. This makes activity stronger and longer in animal models but also increases uncertainty around hypoglycaemia and uncontrolled growth signalling.
1Overview
1× / dayReference frequency
DataAnimal research; human data usually concern other IGF-1 products
Research status
Not approved; no established human protocol
IGF-1 LR31 MG
01 · Overview
What is IGF-1 LR3?
IGF-1 LR3 is an extended IGF-1 analogue with arginine at position 3 and reduced affinity for IGF-binding proteins. This makes activity stronger and longer in animal models but also increases uncertainty around hypoglycaemia and uncontrolled growth signalling.
Research route, formulation and population determine what a result actually means.
02 · Research
What do the studies show?
Animal research; human data usually concern other IGF-1 products. Educational information. Not diagnosis, treatment or use advice.
2–3×
PreclinicalStronger glucose effect
In pigs and primates, IGF-1 variants with weak IGFBP binding lowered glucose more strongly and for longer than native IGF-1.
0 RCT
Limited evidenceNo human LR3 efficacy
Clinical data for mecasermin or native IGF-1 must not be presented as evidence for LR3.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
IGF-1 LR3Peptide and product specifications
Molecular formula
C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
Molecular weight
9117.6 g/mol
CAS number
946870-92-4
Amino-acid sequence / components
Extended IGF-1 analogue (83 amino acids; Arg³, 13-amino-acid N-terminal extension)
Amino-acid count
83
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference form
White lyophilised powder
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
Once daily in educational protocols
1
2
3
4
Draw to
0 units
0.00 mL
IGF-1 LR3
1 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION
How to reconstitute IGF-1 LR3 for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Not approved; no established human protocol. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
IGF-1 LR3 is an extended IGF-1 analogue with arginine at position 3 and reduced affinity for IGF-binding proteins. This makes activity stronger and longer in animal models but also increases uncertainty around hypoglycaemia and uncontrolled growth signalling.
In pigs and primates, IGF-1 variants with weak IGFBP binding lowered glucose more strongly and for longer than native IGF-1. Clinical data for mecasermin or native IGF-1 must not be presented as evidence for LR3.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources
Primary research sources
Educational information. Not diagnosis, treatment or use advice.